T2DM (Type 2 Diabetes Mellitus) Clinical Trial
Official title:
A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM).
This study is designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in subjects with type 2 diabetes mellitus (T2DM). There are two cohorts in this study. Approximately 360 subjects with T2DM will initially undergo a 2-week, single-blind placebo run-in period (Visits 1 and 2), followed by a 12-week treatment period (Visits 3 through 9). Cohort A will enroll 285 subjects; Cohort B will enroll 75 subjects For 265 of the 285 subjects of Cohort A, the total 12-week treatment period will include a Part 1"dose escalation" interval (2 weeks, Visits 3 and 4) and a Part 2 stable dose "maintenance" interval (10 weeks, Visits 5 through 9). In addition, per FDA request, the remaining 20 subjects (of the cohort total of 285 enrolled subjects) will receive excipient-matched placebo in a non-randomized single-blind fashion, TID (3 times per day), according to the same schedule as described above. For Cohort B (75 of the 360 total subjects), the total 12-week treatment period will include a stable dosing period for both Part 1 (2 weeks, Visits 3 and 4) and Part 2 (10 weeks, Visits 5 through 9). Cohort A data will be analyzed after Cohort A data collection has been completed (last subject for Cohort A screened on 7 May 2019). Estimated completion for Cohort A is October 2019. Cohort B data will be analyzed following the release of results from Cohort A. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01373814 -
Nutritional Therapy for Diabetic Cardiomyopathy
|
||
| Recruiting |
NCT05469659 -
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
|
Phase 2 | |
| Completed |
NCT05376930 -
Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.
|
Phase 3 | |
| Recruiting |
NCT04682795 -
Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM
|
N/A | |
| Recruiting |
NCT06350890 -
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
|
Phase 3 | |
| Not yet recruiting |
NCT06094491 -
Virtual Diabetes Group Visits Across Health Systems
|
N/A | |
| Completed |
NCT04634500 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
|
Phase 3 | |
| Recruiting |
NCT03789695 -
RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
|
Phase 4 | |
| Completed |
NCT04632862 -
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
|
Phase 3 | |
| Completed |
NCT04688359 -
Effectiveness of Nurse-coordinated Follow-up Program in Primary Care for People at Risk for T2DM
|
N/A | |
| Completed |
NCT05983289 -
Single Escalating Dose Study Of HSK7653 In Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
| Completed |
NCT05376969 -
Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin
|
Phase 3 | |
| Completed |
NCT05279911 -
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
|
N/A | |
| Active, not recruiting |
NCT03257449 -
Effect of Viscous Soluble Fibres on Body Weight
|
N/A | |
| Terminated |
NCT04754334 -
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
|
Phase 3 | |
| Not yet recruiting |
NCT06293417 -
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
|
||
| Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
| Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A | |
| Completed |
NCT03155087 -
PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
|
N/A |